Hospitals that are participating in Medicare’s mandatory bundled payment model for hip and knee replacements reported a decrease in spending per episode of $812 compared with control hospitals not participating in the Comprehensive Care for Joint Replacement (CJR) program.
Medicare’s Comprehensive Care for Joint Replacement (CJR) mandatory bundled payment model has been in place for 2 years, during which spending has decreased moderately and the rate of complications has stayed the same, according to a new analysis.
The study, published in New England Journal of Medicine, evaluated hip- or knee-replacement episodes from 2015 to 2017 to understand spending per episode, rates of postsurgical complications, and the percentage of “high-risk” patients.
"Interest in bundled payments has exploded the past few years," Michael Barnett, one of the lead authors on the study and assistant professor of health policy and management at Harvard Chan School, said in a statement. "The big question has always been whether this new model can lead hospitals to meaningfully reduce spending without harming patients. This study indicates that, with the right financial incentive, hospitals can save money without compromising quality by sending more patients home rather than to a nursing facility."
The study compared 803 hospitals in 75 metropolitan statistical areas required to participate in CJR with 962 hospitals in 121 control areas. Under CJR, hospitals in areas selected for mandatory participation would receive bonuses or penalties depending on how much they spent on follow-up care after patients receiving hip- or knee-replacements were discharged.
There was a total of 280,161 joint replacements in CJR hospitals and 377,278 procedures in control hospitals. The authors found that spending per joint-replacement episode in hospitals participating in CJR decreased $812 (—3.1%) after the model was implemented compared with spending in control areas.
The authors noted that during the 18-month period, the decrease in payments grew, “which raises the possibility that CJR could lead to greater reductions in payments as hospitals adapt to the new payment model.”
At the same time, there was not an increase in complications, readmissions, or death in hospitals participating in CJR, leading the authors to believe that CJR hospitals may have been able to identify high-risk patients and patients who can safely be discharged home.
The continuing impact of CJR is uncertain, as the Trump administration transitioned the program to a partly voluntary model in March 2018.
“Although the future of mandatory payment models is uncertain, the CJR program helps address the question of whether savings seen in previous evaluations of bundled-payment programs were attributable to the select nature of the hospitals that volunteered,” the authors wrote. “Our findings suggest that the changes observed in voluntary programs may be echoed in mandatory programs.”
Reference
Barnett ML, Wilcock A, McWilliams JM, et al. Two-year evaluation of mandatory bundled payments for joint replacement. [published online January 2, 2019]. N Engl J Med, 2019; doi: 10.1056/NEJMsa1809010.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More